Can AI help create “smart borders” between countries?
In 2016, border patrols in Greece, Latvia and Hungary received a prototype for an AI-powered lie detector to help screen asylum seekers. The detector, called iBorderCtrl, was funded by the European Commission in hopes to eventually mitigate refugee crises like the one sparked by the Syrian civil war a year prior.
iBorderCtrl, which analyzes micro expressions in the face, received but one slice of the Commission’s €34.9 billion border control and migration management budget. Still in development is the more ambitious EuMigraTool, a predictive AI system that will process internet news and social media posts to estimate not only the number of migrants heading for a particular country, but also the “risks of tensions between migrants and EU citizens.”
Both iBorderCtrl and EuMigraTool are part of a broader trend: the growing digitization of migration-related technologies. Outside of the EU, in refugee camps in Jordan, the United Nations introduced iris scanning software to distribute humanitarian aid, including food and medicine. And in the United States, Customs and Border Protection has attempted to automate its services through an app called CBP One, which both travelers and asylum seekers can use to apply for I-94 forms, the arrival-departure record cards for people who are not U.S. citizens or permanent residents.
According to Koen Leurs, professor of gender, media and migration studies at Utrecht University in the Netherlands, we have arrived at a point where migration management has become so reliant on digital technology that the former can no longer be studied in isolation from the latter. Investigating this reliance for his new book, Digital Migration, Leurs came to the conclusion that applications like those mentioned above are more often than not a double-edged sword, presenting both benefits and drawbacks.
There has been “a huge acceleration” in the way digital technologies “dehumanize people,” says Koen Leurs, professor of gender, media and migration studies at Utrecht University in the Netherlands. Governments treat asylum seekers as test subjects for new inventions, all along the borders of the developed world.
On the one hand, digital technology can make migration management more efficient and less labor intensive, enabling countries to process larger numbers of people in a time when global movement is on the rise due to globalization and political instability. Leurs also discovered that informal knowledge networks such as Informed Immigrant, an online resource that connects migrants to social workers and community organizers, have positively impacted the lives of their users. The same, Leurs notes, is true of platforms like Twitter, Facebook, and WhatsApp, all of which migrants use to stay in touch with each other as well as their families back home. “The emotional support you receive through social media is something we all came to appreciate during the COVID pandemic,” Leurs says. “For refugees, this had already been common knowledge for years.”
On the flipside, automatization of migration management – particularly through the use of AI – has spawned extensive criticism from human rights activists. Sharing their sentiment, Leurs attests that many so-called innovations are making life harder for migrants, not easier. He also says there has been “a huge acceleration” in the way digital technologies “dehumanize people,” and that governments treat asylum seekers as test subjects for new inventions, all along the borders of the developed world.
In Jordan, for example, refugees had to scan their irises in order to collect aid, prompting the question of whether such measures are ethical. Speaking to Reuters, Petra Molnar, a fellow at Harvard University’s Berkman Klein Center for Internet and Society, said that she was troubled by the fact that this experiment was done on marginalized people. “The refugees are guinea pigs,” she said. “Imagine what would happen at your local grocery store if all of a sudden iris scanning became a thing,” she pointed out. “People would be up in arms. But somehow it is OK to do it in a refugee camp.”
Artificial intelligence programs have been scrutinized for their unreliability, their complex processing, thwarted by the race and gender biases picked up from training data. In 2019, a female reporter from The Intercept tested iBorderCtrl and, despite answering all questions truthfully, was accused by the machine of lying four out of 16 times. Had she been waiting at checkpoint on the Greek or Latvian border, she would have been flagged for additional screening – a measure that could jeopardize her chance of entry. Because of its biases, and the negative press that this attracted, iBorderCtrl did not move past its test phase.
While facial recognition caused problems on the European border, it was helpful in Ukraine, where programs like those developed by software company Clearview AI are used to spot Russian spies, identify dead soldiers, and check movement in and out of war zones.
In April 2021, not long after iBorderCtrl was shut down, the European Commission proposed the world’s first-ever legal framework for AI regulation: the Artificial Intelligence Act. The act, which is still being developed, promises to prevent potentially “harmful” AI practices from being used in migration management. In the most recent draft, approved by the European Parliament’s Liberties and Internal Market committees, the ban included emotion recognition systems (like iBorderCtrl), predictive policing systems (like EUMigraTool), and biometric categorization systems (like iris scanners). The act also stipulates that AI must be subject to strict oversight and accountability measures.
While some worry the AI Act is not comprehensive enough, others wonder if it is in fact going too far. Indeed, many proponents of machine learning argue that, by placing a categorical ban on certain systems, governments will thwart the development of potentially useful technology. While facial recognition caused problems on the European border, it was helpful in Ukraine, where programs like those developed by software company Clearview AI are used to spot Russian spies, identify dead soldiers, and check movement in and out of war zones.
Instead of flat-out banning AI, why not strive to make it more reliable? “One of the most compelling arguments against AI is that it is inherently biased,” says Vera Raposo, an assistant professor of law at NOVA University in Lisbon specializing in digital law. “In truth, AI itself is not biased; it becomes biased due to human influence. It seems that complete eradication of biases is unattainable, but mitigation is possible. We can strive to reduce biases by employing more comprehensive and unbiased data in AI training and encompassing a wider range of individuals. We can also work on developing less biased algorithms, although this is challenging given that coders, being human, inherently possess biases of their own.”
AI is most effective when it enhances human performance rather than replacing it.
Accessibility is another obstacle that needs to be overcome. Leurs points out that, in migration management, AI often functions as a “black box” because the migration officers operating it are unable to comprehend its complex decision-making process and thus unable to scrutinize its results. One solution to this problem is to have law enforcement work closely with AI experts. Alternatively, machine learning could be limited to gathering and summarizing information, leaving evaluation of that information to actual people.
Raposo agrees AI is most effective when it enhances human performance rather than replacing it. On the topic of transparency, she does note that making an AI that is both sophisticated and easy to understand is a little bit like having your cake and eating it too. “In numerous domains,” she explains, “we might need to accept a reduced level of explainability in exchange for a high degree of accuracy (assuming we cannot have both).” Using healthcare as an analogy, she adds that “some medications work in ways not fully understood by either doctors or pharma companies, yet persist due to demonstrated efficacy in clinical trials.”
Leurs believes digital technologies used in migration management can be improved through a push for more conscientious research. “Technology is a poison and a medicine for that poison,” he argues, which is why new tech should be developed with its potential applications in mind. “Ethics has become a major concern in recent years. Increasingly, and particularly in the study of forced migration, researchers are posing critical questions like ‘what happens with the data that is gathered?’ and ‘who will this harm?’” In some cases, Leurs thinks, that last question may need to be reversed: we should be thinking about how we can actively disarm oppressive structures. “After all, our work should align with the interests of the communities it is going to affect.”
If you look back on the last century of scientific achievements, you might notice that most of the scientists we celebrate are overwhelmingly white, while scientists of color take a backseat. Since the Nobel Prize was introduced in 1901, for example, no black scientists have landed this prestigious award.
The work of black women scientists has gone unrecognized in particular. Their work uncredited and often stolen, black women have nevertheless contributed to some of the most important advancements of the last 100 years, from the polio vaccine to GPS.
Here are five black women who have changed science forever.
Dr. May Edward Chinn
Dr. May Edward Chinn practicing medicine in Harlem
George B. Davis, PhD.
Chinn was born to poor parents in New York City just before the start of the 20th century. Although she showed great promise as a pianist, playing with the legendary musician Paul Robeson throughout the 1920s, she decided to study medicine instead. Chinn, like other black doctors of the time, were barred from studying or practicing in New York hospitals. So Chinn formed a private practice and made house calls, sometimes operating in patients’ living rooms, using an ironing board as a makeshift operating table.
Chinn worked among the city’s poor, and in doing this, started to notice her patients had late-stage cancers that often had gone undetected or untreated for years. To learn more about cancer and its prevention, Chinn begged information off white doctors who were willing to share with her, and even accompanied her patients to other clinic appointments in the city, claiming to be the family physician. Chinn took this information and integrated it into her own practice, creating guidelines for early cancer detection that were revolutionary at the time—for instance, checking patient health histories, checking family histories, performing routine pap smears, and screening patients for cancer even before they showed symptoms. For years, Chinn was the only black female doctor working in Harlem, and she continued to work closely with the poor and advocate for early cancer screenings until she retired at age 81.
Alice Ball
Pictorial Press Ltd/Alamy
Alice Ball was a chemist best known for her groundbreaking work on the development of the “Ball Method,” the first successful treatment for those suffering from leprosy during the early 20th century.
In 1916, while she was an undergraduate student at the University of Hawaii, Ball studied the effects of Chaulmoogra oil in treating leprosy. This oil was a well-established therapy in Asian countries, but it had such a foul taste and led to such unpleasant side effects that many patients refused to take it.
So Ball developed a method to isolate and extract the active compounds from Chaulmoogra oil to create an injectable medicine. This marked a significant breakthrough in leprosy treatment and became the standard of care for several decades afterward.
Unfortunately, Ball died before she could publish her results, and credit for this discovery was given to another scientist. One of her colleagues, however, was able to properly credit her in a publication in 1922.
Henrietta Lacks
onathan Newton/The Washington Post/Getty
The person who arguably contributed the most to scientific research in the last century, surprisingly, wasn’t even a scientist. Henrietta Lacks was a tobacco farmer and mother of five children who lived in Maryland during the 1940s. In 1951, Lacks visited Johns Hopkins Hospital where doctors found a cancerous tumor on her cervix. Before treating the tumor, the doctor who examined Lacks clipped two small samples of tissue from Lacks’ cervix without her knowledge or consent—something unthinkable today thanks to informed consent practices, but commonplace back then.
As Lacks underwent treatment for her cancer, her tissue samples made their way to the desk of George Otto Gey, a cancer researcher at Johns Hopkins. He noticed that unlike the other cell cultures that came into his lab, Lacks’ cells grew and multiplied instead of dying out. Lacks’ cells were “immortal,” meaning that because of a genetic defect, they were able to reproduce indefinitely as long as certain conditions were kept stable inside the lab.
Gey started shipping Lacks’ cells to other researchers across the globe, and scientists were thrilled to have an unlimited amount of sturdy human cells with which to experiment. Long after Lacks died of cervical cancer in 1951, her cells continued to multiply and scientists continued to use them to develop cancer treatments, to learn more about HIV/AIDS, to pioneer fertility treatments like in vitro fertilization, and to develop the polio vaccine. To this day, Lacks’ cells have saved an estimated 10 million lives, and her family is beginning to get the compensation and recognition that Henrietta deserved.
Dr. Gladys West
Andre West
Gladys West was a mathematician who helped invent something nearly everyone uses today. West started her career in the 1950s at the Naval Surface Warfare Center Dahlgren Division in Virginia, and took data from satellites to create a mathematical model of the Earth’s shape and gravitational field. This important work would lay the groundwork for the technology that would later become the Global Positioning System, or GPS. West’s work was not widely recognized until she was honored by the US Air Force in 2018.
Dr. Kizzmekia "Kizzy" Corbett
TIME Magazine
At just 35 years old, immunologist Kizzmekia “Kizzy” Corbett has already made history. A viral immunologist by training, Corbett studied coronaviruses at the National Institutes of Health (NIH) and researched possible vaccines for coronaviruses such as SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome).
At the start of the COVID pandemic, Corbett and her team at the NIH partnered with pharmaceutical giant Moderna to develop an mRNA-based vaccine against the virus. Corbett’s previous work with mRNA and coronaviruses was vital in developing the vaccine, which became one of the first to be authorized for emergency use in the United States. The vaccine, along with others, is responsible for saving an estimated 14 million lives.On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.
Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.
In the realm of cancer, Dr. Song is similarly setting his sights on another group of patients for whom treatment options are few and far between: people with solid tumors. Whereas some gradual progress has been made in treating blood cancers such as certain leukemias in past few decades, solid tumors have been even more of a challenge. But Dr. Song’s approach of using natural killer cells to treat solid tumors is promising. You may have heard of CAR-T, which uses genetic engineering to introduce cells into the body that have a particular function to help treat a disease. NKGen focuses on other means to enhance the 40 plus receptors of natural killer cells, making them more receptive and sensitive to picking out cancer cells.
Paul Y. Song, MD is currently CEO and Vice Chairman of NKGen Biotech. Dr. Song’s last clinical role was Asst. Professor at the Samuel Oschin Cancer Center at Cedars Sinai Medical Center.
Dr. Song served as the very first visiting fellow on healthcare policy in the California Department of Insurance in 2013. He is currently on the advisory board of the Pritzker School of Molecular Engineering at the University of Chicago and a board member of Mercy Corps, The Center for Health and Democracy, and Gideon’s Promise.
Dr. Song graduated with honors from the University of Chicago and received his MD from George Washington University. He completed his residency in radiation oncology at the University of Chicago where he served as Chief Resident and did a brachytherapy fellowship at the Institute Gustave Roussy in Villejuif, France. He was also awarded an ASTRO research fellowship in 1995 for his research in radiation inducible gene therapy.
With Dr. Song’s leadership, NKGen Biotech’s work on natural killer cells represents cutting-edge science leading to key findings and important pieces of the puzzle for treating two of humanity’s most intractable diseases.
Show links
- Paul Song LinkedIn
- NKGen Biotech on Twitter - @NKGenBiotech
- NKGen Website: https://nkgenbiotech.com/
- NKGen appoints Paul Song
- Patient Story: https://pix11.com/news/local-news/long-island/promising-new-treatment-for-advanced-alzheimers-patients/
- FDA Clearance: https://nkgenbiotech.com/nkgen-biotech-receives-ind-clearance-from-fda-for-snk02-allogeneic-natural-killer-cell-therapy-for-solid-tumors/Q3 earnings data: https://www.nasdaq.com/press-release/nkgen-biotech-inc.-reports-third-quarter-2023-financial-results-and-business